Skip to main content
OpenTrials
Completed

NCT Number: NCT04543162

Usefulness of Biomarkers in the Management of Mild Traumatic Brain Injury in Adults (Biotraumap)

The indication of cranial computed tomography (CCT) is difficult to define for patients with mild traumatic brain injury (mTBI). For mTBI patients with a medium risk of intracranial complications, CCT scans are indicated although 90% of them are normal.

The interest of the S100B protein has been widely demonstrated in the management of mTBI in adults. Its serum concentration (for blood sampling drawn less than 3 hours after trauma) can accurately predict a normal CCT scan for mTBI patients with a medium risk of intracranial complications. That's why, serum assay of the S100B protein is routinely used in the Emergency Department of Clermont-Ferrand University Hospital for the treatment of patients with mTBI.

The objective of the study is to optimize the management strategy for mTBI patients by blood testing of new brain biomarkers. These biomarkers are synthesized by brain cells and are released into the blood in case of intracranial lesions.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Other biomarkers of brain damage, involved in the pathophysiology of head trauma, are also known. These are, for example, GFAP (Glial Fibrillary Acidic Protein), UCH-L1 (Ubiquitine Carboxy Terminal Hydrolase L1), NSE (Neurone Specific Enolase), Tau, SBDP (Spectrin Breakdown Products) or NFL (Neurofilament) protein. To date, the too limited number of studies doesn't enable the use of these biomarkers routinely. Therefore we will study the interest of these biomarkers in the management of adult patients' mTBI. We wish to set a collection of biological samples drawn from 1500 patients consulting for mTBI (with a medium risk of intracranial complications) at the Emergency Department of Clermont-Ferrand University Hospital, and requiring an assay of the S100B protein.

The study will take place over a period of 36 months at Clermont-Ferrand University Hospital. Patients cared for mTBI when they come to the Emergency Department will be recruited according to the inclusion criteria. In case of no opposition, when having their blood drawn, one more tube will be drawn per patient. Then, the obtained serum will be frozen at -80 ° C for the next assays of the cerebral biomarkers such as: GFAP, UCH-L1, NSE, Tau, SBDP, NFL, etc. A later 2-weeks' telephone call after the head trauma will be made by a member of the staff of the Department of Biochemistry and Molecular Genetics.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patient, major
  • Patient admitted to the Emergency Department for mTBI, with a medium risk of intracranial lesions according to the SFMU (French Emergency Medicine Society) criteria, for which an S100B protein assay is indicated:
  • GCS score of 15 with at least one associated risk factor: amnesia facts more than 30 minutes before the mTBI loss of consciousness, anti platelet aggregating agent
  • Time between mTBI and blood draw (for the S100B protein assay) less than 3 hours.
  • Patient covered by a Social Security scheme.

Exclusion criteria

  • Patient classified in the high risk group of intracranial lesions according to SFMU criteria :
  • GCS score less than 15, 2 hours after the trauma
  • Focused neurological deficit
  • Post-traumatic convulsion
  • Suspicion of open fracture of the skull or embarrassment
  • Any sign of fracture of the base of the skull (hemotympanum, bilateral periorbital bruise, otorrhea or rhinorrhea of cerebrospinal fluid)
  • Treatment with anticoagulants
  • More than one episode of vomiting.
  • Patient classified in the group at low risk of intracranial lesions according to the SFMU criteria, presenting a GCS score of 15 without any criteria for moderate or high risk groups of intracranial lesions.
  • Patient consulting for moderate or severe head trauma (GCS score less than 13).
  • Refusal of the patient (signature of the opposition form).

Treatment and study plan

Primary outcomes

  1. Diagnostic value of cerebral biomarkers GFAP

    Time frame: Day 0

    Evaluate the diagnostic value of cerebral biomarkers GFAP (ng/L)

  2. Diagnostic value of cerebral biomarkers UCH-L1

    Time frame: Day 0

    Evaluate the diagnostic value of cerebral biomarkers UCH-L1 (ng/L)

  3. Diagnostic value of cerebral biomarkers NSE

    Time frame: Day 0

    Evaluate the diagnostic value of cerebral biomarkers NSE (µg/L)

  4. Diagnostic value of cerebral biomarkers Tau

    Time frame: Day 0

    Evaluate the diagnostic value of cerebral biomarkers TAU (ng/L)

  5. Diagnostic value of cerebral biomarkers SBDP

    Time frame: Day 0

    Evaluate the diagnostic value of cerebral biomarkers SBDP (µg/L)

  6. Diagnostic value of cerebral biomarkers NFL

    Time frame: Day 0

    Evaluate the diagnostic value of cerebral biomarkers NFL (ng/L)

Secondary outcomes

  1. Utility of serum biomarker measurement with respect to reduction of the cost of management

    Time frame: Day 0

    Calculate this cost reduction compared to the cost of a cerebral tomodensitometry

  2. Risk factors (antiplatelet agent) on biomarker results

    Time frame: Day 0

    Collect information from medical records and assess the impact on biomarker results from statistical tests

  3. risk factors (loss of consciousness) on biomarker results

    Time frame: Day 0

    Collect information from medical records and assess the impact on biomarker results from statistical tests

  4. risk factors (amnesia) on biomarker results

    Time frame: Day 0

    Collect information from medical records and assess the impact on biomarker results from statistical tests

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Registry information

Official study title

Usefulness of Biomarkers in the Management of Mild Traumatic Brain Injury in Adults

Acronym: Biotraumap

Important dates

Study start
2019
Primary completion
2024
Study completion
2024
First posted
Sep 10, 2020
Registry last updated
Oct 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.